Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Rhea-AI Summary

Palvella Therapeutics (Nasdaq: PVLA) announced that CEO and Founder Wes Kaupinen will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on June 9, 2026, at 8:40 a.m. ET.

A live and archived webcast will be available on Palvella's website.

Argus Jun 2 session

-7.03% close to close 0.9x rel. volume Open Argus

Details

News Market Reaction – PVLA

On Jun 2, the day this news came out, PVLA closed 7.03% below the previous close.

Data tracked by StockTitan Argus for the Jun 2 session.

Key Figures

Conference edition: 47th Conference date: June 9, 2026 Start time: 8:40 a.m. ET +1 more

Conference edition

47th

Goldman Sachs Annual Global Healthcare Conference 2026

Conference date

June 9, 2026

Scheduled fireside chat date

Start time

8:40 a.m. ET

Fireside chat time at conference

Webcast replay window

90 days

Archived replay availability after fireside chat

Historical Context

5 past events · Latest: May 27

5 events

1. May 27

   IP/patent update

   24h Move

   -1.1%

   New Yale-licensed U.S. patent extending QTORIN pitavastatin protection to 2043.

2. May 21

   Corporate recognition

   24h Move

   +0.4%

   Named Healthcare & Life Sciences Company of the Year at PACT awards.

3. May 20

   Clinical data update

   24h Move

   +0.4%

   New SELVA and TOIVA data supporting QTORIN rapamycin and NDA plans.

4. May 15

   Clinical data update

   24h Move

   -4.0%

   Phase 2 TOIVA data showing strong bleeding and satisfaction outcomes in cVM.

5. May 13

   Listing upgrade

   24h Move

   -4.2%

   Transfer of listing from Nasdaq Capital Market to Nasdaq Global Market.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

clinical-stage, biopharmaceutical, Food and Drug Administration (FDA), webcast

4 terms

clinical-stage medical

"a clinical-stage biopharmaceutical company focused on developing and commercializing"

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

biopharmaceutical medical

"a clinical-stage biopharmaceutical company focused on developing and"

A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.

Food and Drug Administration (FDA) regulatory

"for which there are no U.S. Food and Drug Administration (FDA)-approved therapies"

A U.S. government agency that reviews and approves drugs, medical devices, vaccines, food safety measures and related products before they reach the market. Think of it as a gatekeeper whose decisions, inspections and safety warnings can make or break a product’s ability to sell; investors watch FDA actions closely because approvals speed revenue and failed reviews, delays or recalls can sharply change a company’s value.

webcast technical

"A live webcast of the fireside chat will be available on the Events"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WAYNE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Tuesday, June 9, 2026 at 8:40 a.m. ET.

A live webcast of the fireside chat will be available on the Events and Presentations section of Palvella's website at www.palvellatx.com. An archived replay of the webcast will be available for approximately 90 days following the fireside chat.

About Palvella Therapeutics

Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases and vascular malformations, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella’s second product candidate, QTORIN™ pitavastatin, is currently being developed for the treatment of disseminated superficial actinic porokeratosis. For more information, please visit www.palvellatx.com or follow Palvella on LinkedIn or X (formerly known as Twitter).

QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.

Contact Information

Investors

Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com

Media
Marcy Nanus
Managing Partner, Trilon Advisors LLC
mnanus@trilonadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Palvella Therapeutics (PVLA) present at the Goldman Sachs Global Healthcare Conference 2026?

Palvella Therapeutics will present on June 9, 2026, at 8:40 a.m. ET. According to Palvella, CEO Wes Kaupinen will join a fireside chat during the Goldman Sachs 47th Annual Global Healthcare Conference 2026.

How can investors watch Palvella Therapeutics' (PVLA) fireside chat at the Goldman Sachs 2026 healthcare conference?

Investors can watch the fireside chat via a live webcast on Palvella's website. According to Palvella, access will be provided in the Events and Presentations section at www.palvellatx.com.

Will a replay of Palvella Therapeutics' (PVLA) Goldman Sachs 2026 conference webcast be available?

Yes, a replay will be available for approximately 90 days after the event. According to Palvella, the archived webcast can be accessed on the Events and Presentations section of the company’s website.

What type of company is Palvella Therapeutics (PVLA) presenting at the Goldman Sachs 2026 healthcare conference?

Palvella Therapeutics is a clinical-stage biopharmaceutical company. According to Palvella, it focuses on developing novel therapies for serious, rare skin diseases and vascular malformations that currently have no FDA-approved treatment options in the United States.